![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial CagriSema achieves >20% weight loss](https://figures.semanticscholar.org/a9800c8f0dc40d6d18a09ab6d2f14e71a42af380/7-Figure2-1.png)
coadministered cagrilintide and semaglutide in adults with overweight or obesity
coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial CagriSema achieves >20% weight loss
CagriSema achieves >20% weight loss in adults with obesity. Content TribeMD} 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Cagrilintide & Semaglutide in Overweight Adults (REDEFINE 1) NEJM Med Journal Club New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)
USD28.13
USD59.13
Pay in 4 interest-free payments of $7.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial CagriSema achieves >20% weight loss](https://assets.tribemd.com/cagrisema-achieves-%3E20%-weight-loss-in-adults-with-obesity..jpeg)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial CagriSema achieves >20% weight loss](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3791222780272349212)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial CagriSema achieves >20% weight loss](https://i.ytimg.com/vi/9c6OeOHcevQ/hq720.jpg?sqp=-oaymwEhCK4FEIIDSFryq4qpAxMIARUAAAAAGAElAADIQj0AgKJD&rs=AOn4CLDZIUfSSJe3aW3TklaK3fJ-vgy6dQ)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial CagriSema achieves >20% weight loss](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3699010274317415701)